Table 2

Serotype distribution by site of isolation for noninvasive disease isolates

PCV group and serotypeNo. (%) of noninvasive strains from each isolation siteaTotal no. of strains (% of total)
EarEyeNpTrachOther
PCV7
    19F49 (7.2)1 (1.2)8 (8.6)14 (8.3)3 (8.3)75 (7.1)
    6B3 (0.44)3 (3.6)6 (3.6)1 (2.8)13 (1.2)
    23F4 (0.59)6 (3.6)2 (5.6)12 (1.1)
    9V1 (0.15)1 (1.2)2 (1.2)4 (0.38)
    18C2 (0.30)1 (1.1)3 (0.28)
    41 (0.15)1 (0.60)2 (0.19)
    142 (0.30)2 (0.19)
PCV13
    19A241 (35.6)24 (28.6)29 (31.2)34 (20.2)10 (27.8)338 (31.9)
    320 (3.0)3 (3.6)2 (2.2)4 (2.4)29 (2.7)
    6A15 (2.2)3 (3.6)2 (2.2)5 (3.0)1 (2.8)26 (2.5)
    7F6 (0.89)1 (1.2)1 (1.1)1 (2.8)9 (0.85)
    51 (1.2)1 (0.09)
Non-PCV
    NTb58 (8.6)12 (14.3)13 (14.0)24 (14.3)4 (11.1)111 (10.5)
    35B66 (9.7)11 (13.1)6 (6.5)12 (7.1)2 (5.6)97 (9.3)
    6C36 (5.3)5 (6.0)11 (11.8)12 (7.1)4 (11.1)68 (6.4)
    15B/C41 (6.1)2 (2.4)3 (3.2)9 (5.4)4 (11.1)59 (5.6)
    11A/D/F21 (3.1)5 (6.0)4 (4.3)8 (4.8)38 (3.6)
    33F/A23 (3.4)1 (1.1)5 (3.0)29 (2.7)
    22F/A13 (1.9)4 (4.8)2 (2.2)7 (4.3)1 (2.8)27 (2.6)
    15A/F19 (2.8)1 (1.2)1 (1.1)2 (1.2)23 (2.2)
    1618 (2.7)2 (2.2)2 (1.2)22 (2.1)
    23B7 (1.0)2 (2.2)3 (1.8)12 (1.1)
    23A5 (0.74)2 (2.4)1 (1.1)1 (2.8)9 (0.85)
    9N3 (0.44)1 (1.2)1 (1.1)3 (1.8)8 (0.76)
    35F/47F4 (0.59)2 (2.4)1 (0.60)1 (2.8)8 (0.76)
    7B/C/405 (0.74)2 (1.2)7 (0.66)
    17F/A4 (0.59)3 (1.8)7 (0.66)
    313 (0.44)2 (2.4)1 (0.60)6 (0.57)
    342 (0.30)1 (1.1)1 (0.60)4 (0.38)
    10A/391 (0.15)1 (0.60)1 (2.8)3 (0.28)
    212 (0.30)1 (1.1)3 (0.28)
    12F/B1 (0.15)1 (1.1)2 (0.19)
    11E1 (0.15)1 (0.09)
Total677 (64)84 (7.9)93 (8.8)168 (15.9)36 (3.4)1,058 (100)
  • a Np, nasopharyngeal; Trach, tracheal aspirate; other, isolates from sinus tissue, nasal lacrimal duct, or mastoid.

  • b NT, nontypeable (capsular serotype could not be determined).